Use of anti tumor necrosis factor-alpha monoclonal antibody for ulcerative jejunoileitis |
| |
Authors: | Gulseren Seven Adel Assaad Thomas Biehl Richard A Kozarek |
| |
Institution: | Gulseren Seven, Richard A Kozarek, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA 98101, United StatesAdel Assaad, Department of Pathology, Virginia Mason Medical Center, Seattle, WA 98101, United StatesThomas Biehl, Department of General, Thoracic and Vascular Surgery, Virginia Mason Medical Center, Seattle, WA 98101, United States |
| |
Abstract: | Ulcerative jejunoileitis is an uncommon clinical syndrome consisting of abdominal pain, weight loss associated with diarrhea, and multiple inflammatory ulcerations and strictures of the small bowel. Ulcerative jejunoileitis can complicate established celiac disease or develop in patients de novo. Increased levels of tumor necrosis factor-alpha (TNF-α) in the small intestine of patients with untreated celiac disease are associated with a role in the immune pathogenesis of this disorder. No specific therapy has been shown to change the course of ulcerative jejunoileitis. We report a case of severe ulcerative jejunoileitis previously unresponsive to traditional therapies, including high dose corticosteroids and cyclosporine. The patient had a dramatic resolution of symptoms and a complete normalization of endoscopic findings after anti-TNF-α monoclonal antibody, infliximab (Remicade®). |
| |
Keywords: | Ulcerative jejunoileitis Biologic therapy Tumor necrosis factor-alpha Infliximab |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《世界胃肠病学杂志(英文版)》浏览原始摘要信息 |
|